Personalized at-home neurofeedback compared to long-acting methylphenidate in children with ADHD: NEWROFEED, a European randomized noninferiority trial.
Attention-deficit hyperactivity disorder
methylphenidate
neurofeedback
randomized clinical trial
Journal
Journal of child psychology and psychiatry, and allied disciplines
ISSN: 1469-7610
Titre abrégé: J Child Psychol Psychiatry
Pays: England
ID NLM: 0375361
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
accepted:
15
04
2021
pubmed:
25
6
2021
medline:
11
3
2022
entrez:
24
6
2021
Statut:
ppublish
Résumé
Neurofeedback is considered a promising intervention for the treatment of attention-deficit hyperactivity disorder (ADHD). NEWROFEED is a prospective, multicentre, randomized (3:2), reference drug-controlled trial in children with ADHD aged between 7 and 13 years. The main objective of NEWROFEED was to demonstrate the noninferiority of personalized at-home neurofeedback (NF) training versus methylphenidate in the treatment of children with ADHD. The NF group (n = 111) underwent eight visits and two treatment phases of 16 to 20 at-home sessions with down-training of the theta/beta ratio (TBR) for children with high TBR and enhancing the sensorimotor rhythm (SMR) for the others. The control group (n = 67) received optimally titrated long-acting methylphenidate. The primary endpoint was the change between baseline and endpoint in the Clinician ADHD-RS-IV total score in the per-protocol population (90 NF/59 controls). US National Institute of Health, ClinicalTrials.gov #NCT02778360. Our study failed to demonstrate noninferiority of NF versus methylphenidate (mean between-group difference 8.09 90% CI [8.09; 10.56]). However, both treatment groups showed significant pre-post improvements in core ADHD symptoms and in a broader range of problems. Reduction in the Clinician ADHD-RS-IV total score between baseline and final visit (D90) was 26.7% (SMD = 0.89) in the NF and 46.9% (SMD = 2.03) in the control group. NF effects increased whereas those of methylphenidate were stable between intermediate and final visit. Based on clinicians' reports, the effects of at-home NF were inferior to those of methylphenidate as a stand-alone treatment.
Sections du résumé
BACKGROUND
Neurofeedback is considered a promising intervention for the treatment of attention-deficit hyperactivity disorder (ADHD). NEWROFEED is a prospective, multicentre, randomized (3:2), reference drug-controlled trial in children with ADHD aged between 7 and 13 years. The main objective of NEWROFEED was to demonstrate the noninferiority of personalized at-home neurofeedback (NF) training versus methylphenidate in the treatment of children with ADHD.
METHODS
The NF group (n = 111) underwent eight visits and two treatment phases of 16 to 20 at-home sessions with down-training of the theta/beta ratio (TBR) for children with high TBR and enhancing the sensorimotor rhythm (SMR) for the others. The control group (n = 67) received optimally titrated long-acting methylphenidate. The primary endpoint was the change between baseline and endpoint in the Clinician ADHD-RS-IV total score in the per-protocol population (90 NF/59 controls).
TRIAL REGISTRATION
US National Institute of Health, ClinicalTrials.gov #NCT02778360.
RESULTS
Our study failed to demonstrate noninferiority of NF versus methylphenidate (mean between-group difference 8.09 90% CI [8.09; 10.56]). However, both treatment groups showed significant pre-post improvements in core ADHD symptoms and in a broader range of problems. Reduction in the Clinician ADHD-RS-IV total score between baseline and final visit (D90) was 26.7% (SMD = 0.89) in the NF and 46.9% (SMD = 2.03) in the control group. NF effects increased whereas those of methylphenidate were stable between intermediate and final visit.
CONCLUSIONS
Based on clinicians' reports, the effects of at-home NF were inferior to those of methylphenidate as a stand-alone treatment.
Substances chimiques
Central Nervous System Stimulants
0
Methylphenidate
207ZZ9QZ49
Banques de données
ClinicalTrials.gov
['NCT02778360']
Types de publication
Equivalence Trial
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
187-198Informations de copyright
© 2021 Association for Child and Adolescent Mental Health.
Références
Arnold, L.E., Arns, M., Barterian, J., Bergman, R., Black, S., Conners, C.K., … & Williams, C.E. (2020). Double-blind placebo-controlled randomized clinical trial of neurofeedback for attention-deficit/hyperactivity disorder with 13-month follow-up. Journal of the American Academy of Child and Adolescent Psychiatry. https://doi.org/10.1016/j.jaac.2020.07.906
Arns, M., Heinrich, H., & Strehl, U. (2014). Evaluation of neurofeedback in ADHD: The long and winding road. Biological Psychology, 95, 108-115.
Biederman, J., Faraone, S.V., Monuteaux, M.C., & Grossbard, J.R. (2004). How informative are parent reports of attention-deficit/hyperactivity disorder symptoms for assessing outcome in clinical trials of long-acting treatments? A pooled analysis of parents’ and teachers’ reports. Pediatrics, 113, 1667-1671.
Bioulac, S., Purper-Ouakil, D., Ros, T., Blasco-Fontecilla, H., Prats, M., Mayaud, L., & Brandeis, D. (2019). Personalized at-home neurofeedback compared with long-acting methylphenidate in an European non-inferiority randomized trial in children with ADHD. BMC Psychiatry, 19, 237.
Bruni, O., Ottaviano, S., Guidetti, V., Romoli, M., Innocenzi, M., Cortesi, F., & Giannotti, F. (1996). The Sleep Disturbance Scale for Children (SDSC). Construction and validation of an instrument to evaluate sleep disturbances in childhood and adolescence. Journal of Sleep Research, 5, 251-261.
Busner, J., & Targum, S.D. (2007). The clinical global impressions scale: Applying a research tool in clinical practice. Psychiatry, 4, 28-37.
Bussalb, A., Collin, S., Barthélemy, Q., Ojeda, D., Bioulac, S., Blasco-Fontecilla, H., … & Mayaud, L. (2019). Is there a cluster of high theta-beta ratio patients in attention deficit hyperactivity disorder? Clinical Neurophysiology, 130, 1387-1396.
Bussalb, A., Congedo, M., Barthélemy, Q., Ojeda, D., Acquaviva, E., Delorme, R., & Mayaud, L. (2019). Clinical and experimental factors influencing the efficacy of neurofeedback in ADHD: A meta-analysis. Frontiers in Psychiatry, 10, 35.
Conners, C.K. (2014). Conners continuous performance test- third edition (Conners CPT 3) & Conners Continuous Auditory Test of Attention (Conners CATA): Technical Manual. New York: Multi-Health Systems Inc.
Cortese, S., Ferrin, M., Brandeis, D., Holtmann, M., Aggensteiner, P., Daley, D., … & Zuddas, A. (2016). Neurofeedback for attention-deficit/hyperactivity disorder: Meta-analysis of clinical and neuropsychological outcomes from randomized controlled trials. Journal of the American Academy of Child and Adolescent Psychiatry, 55, 444-455.
Daley, D., Van Der Oord, S., Ferrin, M., Cortese, S., Danckaerts, M., Doepfner, M., … & Sonuga-Barke, E.J. (2018). Practitioner Review: Current best practice in the use of parent training and other behavioural interventions in the treatment of children and adolescents with attention deficit hyperactivity disorder. Journal of Child Psychology and Psychiatry, 59, 932-947.
DuPaul, G.J. (1998). ADHD rating-scale-IV: Checklists, norms and clinical interpretation. New York: Guilford Press.
Duric, N.S., Assmus, J., Gundersen, D., & Elgen, I.B. (2012). Neurofeedback for the treatment of children and adolescents with ADHD: A randomized and controlled clinical trial using parental reports. BMC Psychiatry, 12, 107.
Gazer-Snitovsky, M., Brand-Gothelf, A., Dubnov-Raz, G., Weizman, A., & Gothelf, D. (2019). High familial correlation in methylphenidate response and side effect profile. Journal of Attention Disorders, 23, 135-139.
Gevensleben, H., Holl, B., Albrecht, B., Vogel, C., Schlamp, D., Kratz, O., … & Heinrich, H. (2009). Is neurofeedback an efficacious treatment for ADHD? A randomised controlled clinical trial. Journal of Child Psychology and Psychiatry, 50, 780-789.
Goodman, R. (1997). The Strengths and Difficulties Questionnaire: A research note. Journal of Child Psychology and Psychiatry, 38, 581-586.
Hall, C.L., Valentine, A.Z., Groom, M.J., Walker, G.M., Sayal, K., Daley, D. … & Hollis, C. (2016). The clinical utility of the continuous performance test and objective measures of activity for diagnosing and monitoring ADHD in children: A systematic review. European Child and Adolescent Psychiatry, 25, 677-699.
Kaufman, J., Birmaher, B., Brent, D., Rao, U., Flynn, C., Moreci, P., … & Ryan, N. (1997). Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): Initial reliability and validity data. Journal of the American Academy of Child and Adolescent Psychiatry, 36, 980-988.
Mahone, E.M., Cirino, P.T., Cutting, L.E., Cerrone, P.M., Hagelthorn, K.M., Hiemenz, J.R., … & Denckla, M.B. (2002). Validity of the behavior rating inventory of executive function in children with ADHD and/or Tourette syndrome. Archives of Clinical Neuropsychology, 17, 643-662.
March, J., Karayal, O., & Chrisman, A. (2007). CAPTN: The Pediatric Adverse Event Rating Scale. The 2007 Annual Meeting of the American Academy of Child and Adolescent Psychiatry; 2007 23-28 October 2007; Boston, 241.
Minder, F., Zuberer, A., Brandeis, D., & Drechsler, R. (2018). Informant-related effects of neurofeedback and cognitive training in children with ADHD including a waiting control phase: A randomized-controlled trial. European Child and Adolescent Psychiatry, 27, 1055-1066.
Monastra, V.J., Monastra, D.M., & George, S. (2002). The effects of stimulant therapy, EEG biofeedback, and parenting style on the primary symptoms of attention-deficit/hyperactivity disorder. Applied Psychophysiology and Biofeedback, 27, 231-249.
National Institute for Health and Care Excellence (2018). Attention deficit hyperactivity disorder: diagnosis and management (NICE Guideline). Available from: nice.org.uk/ guidance/ng87 [last accessed 27 November 2020].
Posner, K., Brown, G.K., Stanley, B., Brent, D.A., Yershova, K.V., Oquendo, M.A., … & Mann, J.J. (2011). The Columbia-Suicide Severity Rating Scale: Initial validity and internal consistency findings from three multisite studies with adolescents and adults. American Journal of Psychiatry, 168, 1266-1277.
Riley, A.W., Forrest, C.B., Starfield, B., Rebok, G.W., Robertson, J.A., & Green, B.F. (2004). The parent report form of the CHIP-child edition: Reliability and validity. Medical Care, 42, 210-220.
Ros, T., Baars, B.J., Lanius, R.A., & Vuilleumier, P. (2014). Tuning pathological brain oscillations with neurofeedback: a systems neuroscience framework. Frontiers in Human Neuroscience, 8, 1008. https://doi.org/10.3389/fnhum.2014.01008
Ros, T., Enriquez-Geppert, S., Zotev, V., Young, K.D., Wood, G., Whitfield-Gabrieli, S., … & Thibault, R.T. (2020). Consensus on the reporting and experimental design of clinical and cognitive-behavioural neurofeedback studies (CRED-nf checklist). Brain, 143, 1674-1685. https://doi.org/10.1093/brain/awaa009
Sonuga-Barke, E.J.S., Brandeis, D., Cortese, S., Daley, D., Ferrin, M., Holtmann, M., … & Sergeant, J. (2013). Nonpharmacological interventions for ADHD: Systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments. American Journal of Psychiatry, 170, 275-289.
Steele, M., Jensen, P.S., & Quinn, D.M. (2006). Remission versus response as the goal of therapy in ADHD: A new standard for the field? Clinical Therapeutics, 28, 1892-1908.
Strehl, U., Aggensteiner, P., Wachtlin, D., Brandeis, D., Albrecht, B., Arana, M., … & Holtmann, M. (2017). Neurofeedback of slow cortical potentials in children with attention-deficit/hyperactivity disorder: A multicenter randomized trial controlling for unspecific effects. Frontiers in Human Neuroscience, 11, 135.
Van Doren, J., Arns, M., Heinrich, H., Vollebregt, M.A., Strehl, U., & Loo, S.K. (2018). Sustained effects of neurofeedback in ADHD: a systematic review and meta-analysis. European Child and Adolescent Psychiatry, 28, 293-305.
Yan, L., Wang, S., Yuan, Y., & Zhang, J. (2019). Effects of neurofeedback versus methylphenidate for the treatment of ADHD: Systematic review and meta-analysis of head-to-head trials. Evidence Based Mental Health, 22, 111-117.
Zhang, S., Faries, D.E., Vowles, M., & Michelson, D. (2005). ADHD rating scale IV: psychometric properties from a multinational study as clinician-administered instrument. International Journal of Methods in Psychiatric Research, 14, 186-201.
Zuberer, A., Minder, F., Brandeis, D., & Drechsler, R. (2018). Mixed-effects modeling of neurofeedback self-regulation performance: Moderators for learning in children with ADHD. Neural Plasticity, 2018, 2464310.